RecruitingPhase 2NCT04128072
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
Studying Primary cutaneous anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Pablo Luis Ortiz RomeroHospital Universitario 12 De Octubre,Madrid, Spain
- Intervention
- Mogamulizumab(drug)
- Enrollment
- 43 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (13)
- University Hospitals Copenhagen - Rigshospitalet, Copenhagen, Denmark
- CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre, Bordeaux, France
- Assistance Publique Hopitaux Paris- APHP Nord - Univ De Paris Cite - Hop. Saint Louis, Paris, France
- UniversitaetsMedizin Mannheim, Mannheim, Germany
- Muehlenkreiskliniken Johannes Wesling Klinikum Minden, Minden, Germany
- Athens University - Attikon University General Hospital, Athens, Greece
- Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
- Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale San Lazzaro, Torino, Italy
- Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
- Hospital Universitario 12 De Octubre, Madrid, Spain
- Hospital Universitario Puerta De Hierro, Madrid, Spain
- University Hospitals Birmingham NHS Foundation Trust (UHB) -Queen Elizabeth Medical Centre, Birmingham, United Kingdom
- The Christie NHS Foundation Trust, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04128072 on ClinicalTrials.gov